Literature DB >> 11173142

Intensity modulated radiation therapy (IMRT) following prostatectomy: more favorable acute genitourinary toxicity profile compared to primary IMRT for prostate cancer.

B S Teh1, W Y Mai, M E Augspurger, B M Uhl, J McGary, L Dong, W H Grant, H H Lu, S Y Woo, L S Carpenter, J K Chiu, E B Butler.   

Abstract

PURPOSE: To report our initial experience on postprostatectomy IMRT (PPI), addressing acute genitourinary (GU) toxicity in comparison to primary IMRT (PI) for prostate cancer. METHODS AND MATERIALS: From April 1998 to December 1999, 40 postprostatectomy patients were treated with intensity modulated radiation therapy (IMRT) to a median prescribed dose of 64 Gy (mean dose of 69 Gy). The Radiation Therapy Oncology Group (RTOG) scoring system was used to assess acute GU toxicity. Target volume and maximum and mean doses were evaluated. The mean doses to the bladder and irradiated bladder volume receiving >65 Gy were assessed. These were compared to those of 125 patients treated with PI to a prescribed dose of 70 Gy (mean dose of 76 Gy).
RESULTS: The acute GU toxicity profile is more favorable in the PPI group with 82.5% of Grade 0-1 and 17.5% of Grade 2 toxicity compared to 59.2% and 40.8%, respectively, in the PI group (p < 0.001). There was no Grade 3 or higher toxicity in either group. The target volume was larger in the PPI group, while the maximum and mean doses to the target were higher in the PI group. The mean dose delivered to the bladder was higher in the PPI group. The irradiated bladder volume receiving >65 Gy was significantly larger in the PI group (p < 0.001).
CONCLUSIONS: PPI can be delivered with acceptable ute GU toxicity. The larger PPI target volume may be related to the difficulty in delineating prostatic fossa. Despite a larger target volume and a higher mean dose to the bladder, PPI produced a more favorable acute GU toxicity profile. This may be related to a combination of lower mean and maximum doses and smaller bladder volumes receiving >65 Gy in the PPI group, as well as urethral rather than bladder irradiation. The findings have implications in the evaluation of IMRT treatment plan for prostate cancer, whereby the irradiated bladder volumes above 65 Gy may be more meaningful than the mean dose to the bladder. Longer term toxicity results are awaited.

Entities:  

Mesh:

Year:  2001        PMID: 11173142     DOI: 10.1016/s0360-3016(00)01474-7

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  14 in total

1.  Radiotherapy in ophthalmology : 2004 Jules Gonin lecture of the Retina Research Foundation.

Authors:  Leonidas Zografos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-07       Impact factor: 3.117

2.  Costs of early adjuvant radiation therapy after radical prostatectomy: a decision analysis.

Authors:  T N Showalter; K A Foley; E Jutkowitz; C D Lallas; E J Trabulsi; L G Gomella; A P Dicker; L T Pizzi
Journal:  Ann Oncol       Date:  2011-06-09       Impact factor: 32.976

3.  Detailed dosimetric evaluation of intensity-modulated radiation therapy plans created for stage C prostate cancer based on a planning protocol.

Authors:  Yoshiki Norihisa; Takashi Mizowaki; Kenji Takayama; Yuki Miyabe; Kiyotomo Matsugi; Yukinori Matsuo; Masaru Narabayashi; Katsuyuki Sakanaka; Akira Nakamura; Yasushi Nagata; Masahiro Hiraoka
Journal:  Int J Clin Oncol       Date:  2011-09-29       Impact factor: 3.402

4.  Prostate bed target interfractional motion using RTOG consensus definitions and daily CT on rails : Does target motion differ between superior and inferior portions of the clinical target volume?

Authors:  Vivek Verma; Shifeng Chen; Sumin Zhou; Charles A Enke; Andrew O Wahl
Journal:  Strahlenther Onkol       Date:  2016-12-01       Impact factor: 3.621

5.  Prostate bed motion during intensity-modulated radiotherapy treatment.

Authors:  Tracy Klayton; Robert Price; Mark K Buyyounouski; Mark Sobczak; Richard Greenberg; Jinsheng Li; Lanea Keller; Dennis Sopka; Alexander Kutikov; Eric M Horwitz
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-02-11       Impact factor: 7.038

Review 6.  Therapy of recurrent disease after radical prostatectomy in 2007.

Authors:  Rudolf Schwarz; Markus Graefen; Andreas Krüll
Journal:  World J Urol       Date:  2007-02-28       Impact factor: 4.226

Review 7.  The role of indium-111 radioimmunoscintigraphy in post-radical retropubic prostatectomy management of prostate cancer patients.

Authors:  Ashesh B Jani; Stanley L Liauw; Michael J Blend
Journal:  Clin Med Res       Date:  2007-06

8.  Intensity modulated radiotherapy for localized prostate cancer: rigid compliance to dose-volume constraints as a warranty of acceptable toxicity?

Authors:  Michael J Chen; Eduardo Weltman; Rodrigo M Hanriot; Fábio P Luz; Paulo J Cecílio; José C da Cruz; Frederico R Moreira; Adriana S Santos; Lidiane C Martins; Wladmir Nadalin
Journal:  Radiat Oncol       Date:  2007-01-15       Impact factor: 3.481

9.  Three Years of Salvage IMRT for Prostate Cancer: Results of the Montpellier Cancer Center.

Authors:  Olivier Riou; Pascal Fenoglietto; Benoit Laliberté; Cathy Menkarios; Carmen Llacer Moscardo; Meng Huor Hay; Norbert Ailleres; Jean-Bernard Dubois; Xavier Rebillard; David Azria
Journal:  ISRN Urol       Date:  2012-03-20

Review 10.  Locally advanced prostate cancer.

Authors:  E A Klein; P A Kupelian; R Dreicer; D Peereboom; C Zippe
Journal:  Curr Treat Options Oncol       Date:  2001-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.